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Abstract: Buspirone is an anxiolytic drug with robust serotonin receptor 1A (Htr1a) agonist activities.
However, evidence has demonstrated that this drug also targets the dopamine D3 receptor (Drd3),
where it acts as a potent antagonist. In vivo, Drd3 blockade is neuroprotective and reduces inflamma-
tion in models of Parkinson’s disease. To test if buspirone also elicited anti-inflammatory activities
in vitro, we generated stable Drd3−/− and Htr1a−/− BV2 microglial cell lines using CRISPR-Cas9
technology and then tested the effects of buspirone after lipopolysaccharide (LPS) challenge. We
found that LPS exposure had no effect on cell viability, except in Htr1a−/− cells, where viability was
reduced (p < 0.001). Drug treatment reduced viability in Drd3−/− cells, but not in WT or Htr1a−/−
cells. Buspirone counteracted LPS-induced NO release, NOS2, IL-1β and TNF-α gene expression
in WT cells, whereas it exerted limited effects in Drd3−/− or Htr1a−/− microglia. In summary, our
findings indicate that buspirone attenuates microglial polarization after LPS challenge. These results
also highlight some major effects of Drd3 or Htr1a genetic ablation on microglial biology, raising
important questions on the complex role of neurotransmitters in regulating microglia functions.
Keywords: microglia; dopamine D3 receptor; 5-hydroxytryptamine 1a receptor; neuroinflammation;
Parkinson’s disease
1. Introduction
Buspirone (Buspar®) is a FDA-approved selective 5-hydroxytryptamine receptor (5-
HT1Ar) partial agonist used in the treatment of generalised anxiety disorder [1]. It is well
known that 5-hydroxytryptamine, or serotonin (5-HT) regulates both mood and sleep, and
drugs that stimulate 5-HT activity are commonly used therapeutically for anxiety and
depression [2,3]. However, it has also been shown that Buspirone has a strong “off-target”
function as a dopamine-3-receptor (Drd3) antagonist [4–6].
Drd3’s are found mainly in the striatum, particularly within the nucleus accumbens
where they are involved in the regulation of motor function, impulse control, memory
performance, addiction and drug tolerance [6–10]. However, a novel role for dopamine
receptors (DRs) in neuroinflammation has been revealed [11]. McKenna and colleagues,
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showed that functional DRs are expressed on the surface of multiple immune cell types
including microglia [12].
Dopamine (DA) can exert its effects through interactions with any of the five DRs
expressed on the membrane of target cells [13]. This is seen clearly in the ability of the Drd3
to promote inflammation [14]. For example, Elgueta et al. [15] showed that Drd3-signalling
promotes the development of PD by favoring neuroinflammation and the pathogenic
CD4+ T cell response associated with Parkinson’s disease (PD) [15]. Furthermore, studies
using experimental compounds have shown that blocking the Drd3, significantly reduced
inflammation and consequently slowed the progression of PD [11,15].
PD is a progressive neurodegenerative disorder characterised by a loss of dopaminer-
gic neurons in the substantia nigra pars compacta resulting in diminished DA availability in
the striatum [16]. PD is also associated with chronic neuroinflammation [17]. As such, the
abnormal DA signalling observed in PD could contribute not only to altered DA neurotrans-
mission, but also to an altered immune response. This is particularly important as evidence
from studies of LPS-mediated neurotoxicity [18] has shown that inflammatory responses
from non-neuronal cells alone are sufficient to cause loss of DAergic neurons. Injection of
LPS into the rodent brain results in increased levels of inflammatory mediators, including
cyclooxygenase-2 (COX-2) and inducible nitric oxide synthetase (iNOS), prior to the loss of
DA-ergic neurons [19]. This suggests that inflammation may precede neurodegeneration,
which ultimately results in PD. Accordingly, blocking Drd3-mediated signalling presents a
promising targeted therapeutic strategy for PD.
Neuroinflammation describes the local inflammatory response within the brain and
is driven predominantly by microglia, the specialised scavengers of the brain [20,21].
Normally, microglia exist in a resting state and contribute to immune surveillance [22]. In
response to injury or pathological stimuli, microglia become activated and release cytotoxic
and pro-inflammatory molecules [23], which have been shown to promote the degeneration
of DA neurons [24]. This has been shown in several studies in which the chronic activation
of microglia exacerbates neurodegeneration, as the excessive and sustained secretion of
neurotoxic molecules such as nitric oxide (NO) and pro-inflammatory cytokines become
detrimental to neighboring neuronal cells [24]. DA receptors expressed by microglia appear
to modulate inflammatory responses and neuronal survival [25]. For example, it has been
shown that microglial activation is prevented in Drd3-deficient mice, in the MPTP-(1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-model of PD [15]. Furthermore, the anti-PD
drug rasagiline, a brain-selective MAO inhibitor, significantly reduced both reactive oxygen
species (ROS) and NO secretion, as well as cytokine release in DA stimulated microglia [26].
Collectively, these results suggest that DA can hamper the ability of microglia to secrete
cytokines and shift towards activated phenotypes.
Since microglia are the key drivers of neuroinflammation, it is crucial to determine
how Drd3-mediated activity regulates these cells. For example, in PD it is well accepted
that neuroinflammation drives progressive neurodegeneration. In fact, neuronal damage
and uncontrolled inflammation amplify each other to induce a feed-forward vicious cycle
driving the chronic progression of PD and other neurodegenerative diseases [27]. These
observations underpin the substantial experimental efforts in exploring the potential utility
of traditional anti-inflammatory drugs able to slow, reverse and prevent PD [11]. However,
due to the peripheral effects of the long-term use of anti-inflammatory drugs, novel targets
are needed specifically to counteract CNS inflammation. Studies using experimental
compounds that block the Drd3 pharmacologically could help in determining whether
targeting these receptors may provide a viable disease-modifying strategy to reduce chronic
inflammation in PD, and perhaps for other neuroinflammatory disorders [11].
Buspirone could be one such drug. Therefore, in this study, we sought to investigate
whether buspirone prevents inflammation in microglial cells exposed to the inflammatory
mimetic LPS. To the best of our knowledge, no other studies have tested these effects
in microglia. In the established BV-2 microglial cell line, we implemented CRISPR-Cas9
technology to generate two independent cell lines harboring a targeted Drd3 or Htr1a
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gene deletion, Buspirone’s best known pharmacological targets. We used a combination of
molecular and cellular biological techniques to investigate: (i) the viability of these cells
following gene deletion, and (ii) the functional consequences of gene deletions in response
to the inflammatory mimetic, lipopolysaccharide (LPS).
2. Materials and Methods
2.1. Generation of Knockout Cell Lines Using CRISPR-Cas9 Gene Editing
The CRISPR-Cas9 plasmid Px458 was used to generate knockout cell lines, as pre-
viously described [28]. Guide RNA (gRNA) sequences (summarised in Table 1) were
generated using the online design tool Benchling and synthesised by Sigma-Aldrich (Castle
Hill, NSW, Australia). Plasmids were cloned in DH5-α Escherichia coli and, after a single
colony selection from ampicillin positive (100 µg/mL) plates, extracted using the GeneJET
Plasmid Miniprep Kit (ThermoFisher Scientific, North Ryde, NSW, Australia). Transfec-
tion was carried out in a 12-well plate with a seeding density of 1 × 105 cells per well.
Cells were transfected in 3 µL of Lipofectamine 3000 (Invitrogen) diluted in 62.5 µL of
Opti-MEM (ThermoFisher Scientific). This was combined with a DNA mixture containing
2 µg of purified plasmid, 4 µL of P3000 reagent (Invitrogen, Carlsbad, CA, USA) and
125 µL of Opti-MEM (Thermofisher Scientific). Cells were incubated in the mixture for 4 h
at 37 ◦C with 5% CO2. After incubation, half of the mixture was removed and replaced
with Opti-MEM and incubated for 24 h at 37 ◦C with 5% CO2. Transfected cells were
then single-cell sorted into a 96-well plate using the MoFlo© Astrios Cell Sorter, gating
for green fluorescent protein (GFP) positive cells. Single-cell-derived colonies (isogenic
populations) were expanded for biochemical and molecular analysis. To identify the status
of genome editing, genomic DNA was extracted from the isogenic populations using
ISOLATE II Genomic DNA Kit (Bioline, NSW, Australia), and end-point PCR amplification
was conducted with MyTaq DNA Polymerase Kit (Bioline), using primer sets described
in Table 2. The amplification took place in the T100 Thermal Cycler (Bio-Rad, Gladesville,
NSW, Australia) under the following instrument settings: (1) 95 ◦C for 60 s, (2) 95 ◦C
for 15 s, (3) 56 ◦C for 15 s, (4) 72 ◦C for 10 s, (5) repeat step 2–4 for 35 cycles. Following
end-point PCR, we confirmed that the primers amplified the correct product by Agarose
Gel Electrophoresis (AGE) (Supplementary Figure S3). Following confirmation by AGE,
PCR products were purified using SureClean Plus (Bioline) and sent to Australian Genome
Research Facility (AGRF) for Sanger sequencing using the primers described in Table 3.
Sanger sequencing results were analysed using online tools Benchling and Tracking of
Indels by Decomposition: TIDE.
Table 1. Guide RNA (gRNA) primers used to target the mouse Drd3 and Htr1a genes with the CRISPR-Cas9 plasmid.
Gene (Ref. Seq.) Forward Sequence 5
′-3′
Reverse Sequence 3′-5′ Location Tm (
◦C)










Table 2. PCR primers used to amplify the mouse Drd3 and Htr1a genes.
Gene (Ref. Seq.) Forward Sequence 5
′-3′
Reverse Sequence 3′-5′ Location Tm (
◦C) Length (BP)
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Table 3. Primers used for the sequencing of the mouse Drd3 and Htr1a genes.
Gene (Ref. Seq.) Forward Sequence 5
′-3′
Reverse Sequence 3′-5′ Location Tm (
◦C) Length (BP)











Mouse microglial BV-2 cells were used in this study. These cells share a high tran-
scriptome homology and response to inflammatory challenges with primary microglia [29].
Cells were grown in full growth media containing Dulbecco’s modified eagle’s medium
nutrient mixture F-12 HAM (1:1 vol/vol DMEM/F12) (Sigma-Aldrich, Castle Hill, NSW,
Australia), 10% heat-inactivated foetal bovine serum (FBS, Sigma-Aldrich, Castle Hill,
NSW, Australia) and 1% penicillin/streptomycin solution (Sigma-Aldrich, Castle Hill,
NSW, Australia) and were kept in an incubator with humidified air containing 5% CO2
at a temperature of 37 ◦C. Cells were treated with 1 µg/mL LPS (L4391, Escherichia coli
0111: B4, Sigma-Aldrich) and/or 300 µM buspirone (Sigma-Aldrich) for 24 h at 37 ◦C in a
humidified atmosphere with 5% CO2. LPS concentrations and buspirone concentrations
used in this study were based on preliminary observations (data not shown).
2.3. Cell Viability
To assess cell viability, we used the Cell Proliferation Kit I (MTT) (Sigma-Aldrich).
Cells were seeded at 2 × 104 cells per well in a 96-well plate and incubated at 37 ◦C with
5% CO2 until cells reached 80% confluence. Cells were treated for 24 h with control media,
1 µg/mL LPS or both LPS and 300 µM buspirone. After 24 h, 10 µL of MTT labelling
reagent was added to each well. After 4 h, 100 µL of the solubilization solution (10% SDS
in 0.01 M HCl) was added to each well and incubated at 37 ◦C overnight. Absorbance
was measured at 565 nm in the TECAN infinite M1000-PRO ELISA reader (ThermoFisher
Scientific).
2.4. Nitric Oxide (Griess Reagent Assay)
Cells were seeded at 2 × 104 cells per well in a 96-well plate and incubated at 37 ◦C
with 5% CO2 until cells reached 80% confluence. Cells were treated for 24 h with control
media, 1 µg/mL LPS or both LPS and 300 µM buspirone. The supernatant was collected
and placed into a new 96-well plate. A total of 100 µL of freshly prepared Griess reagent
was then added to each well and incubated at room temperature for 15 min on a slow
oscillation protected from light. Absorbance was measured at 540 nm using the TECAN
infinite M1000-PRO ELISA reader. Optical density values from each group were recorded
and reported as a percentage of control.
2.5. RNA Extraction and cDNA Synthesis
Total RNA was extracted using 1 mL TRI reagent (Sigma-Aldrich, Castle Hill, NSW,
Australia) and 0.2 mL chloroform and precipitated with 0.5 mL 2-propanol (Sigma-Aldrich).
Pellets were washed twice with 75% ethanol and air-dried. RNA concentrations were
calculated using NanoDrop™ 2000 (ThermoFisher Scientific). A total of 1 µg of total RNA
were loaded in each cDNA synthesis reaction. cDNA synthesis was conducted using the
T1000 thermal cycler (Bio-Rad, Gladesville, NSW, Australia) in a final volume of 20 µL.
Each reaction contained 1 µg of RNA diluted in a volume of 11 µL, to which we added
9 µL of cDNA synthesis mix (Tetro cDNA synthesis kit) (Bioline, Australia). Samples were
incubated at 45 ◦C for 40 min followed by 85 ◦C for 5 min. Finally, cDNA samples were
stored at −20 ◦C until use.
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2.6. Real-Time Quantitative Polymerase Chain Reaction
Real-time qPCR analyses were carried out as previously reported [30,31], with minor
modifications. For each gene of interest, qPCRs were performed in a final volume of 10 µL,
which comprised 3 µL cDNA, 0.4 µL milliQ water, 5 µL of iTaq Universal SYBR green
master mix (BioRad, Gladesville, NSW, Australia) and 0.8 µL of the corresponding forward
and reverse primers (5 µM, Sigma-Aldrich, Castle Hill, NSW, Australia) to obtain a final
primer concentration of 400 nM. The primers are described in Table 4. Reaction mixtures
were loaded in Hard-Shell® 96-Well PCR Plates, and four genes of interest were tested in
each run using the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Gladesville,
NSW, Australia). Instrument settings were as follows: (1) 95 ◦C for 2 min, (2) 60 ◦C for 10 s,
(3) 72 ◦C for 10 s, (4) plate read, (5) repeat step 2 to 4 for 45 cycles. For the melting curve
analyses, settings were (1) 65 ◦C for 35 s, (2) plate read, (3) repeat step 1–2 for 60 times). To
examine changes in expression, we analysed the mean fold change values of each sample,
calculated using the ∆∆Ct method, as previously described by Schmittgen and Livak [32].
PCR product specificity was evaluated by melting curve analysis, with each gene showing
a single peak (data not shown).
Table 4. List of primers sets used in real-time quantitative PCR analyses.
Gene GeneBank Accession Number Primer Sequence Length (bp)
S18 NM_011296.2 Fwd 5
′ CCCTGAGAAGTTCCAGCACA 3′
Rev 5′ GGTGAGGTCGATGTCTGCTT 3′ 145
Drd3 NM_007877 Fwd 5
′ GGGGTGACTGTCCTGGTCTA 3′
Rev 5′ AAGCCAGGTCTGATGCTGAT 3′ 100
IL-1β NM_008361.4 Fwd 5
′ GCTACCTGTGTCTTTCCCGT 3′
Rev 5′ CATCTCGGAGCCTGTAGTGC 3′ 164
TNF-α NM_013693.3 Fwd 5
′ ATGGCCTCCCTCTCATCAGT 3′
Rev 5′ TTTGCTACGACGTGGGCTAC 3′ 97
FIZZ1 NM_020509.3 Fwd 5
′ AGCTGATGGTCCCAGTGAAT 3′
Rev 5′ AGTGGAGGGATAGTTAGCTGG 3′ 98
Arg1 NM_007482.3 Fwd 5
′ ACAAGACAGGGCTCCTTTCAG 3′
Rev 5′ TTAAAGCCACTGCCGTGTTC 3′ 105
NOS2 NM_010927.4 Fwd 5
′ TACCAAAGTGACCTGAAAGAGG 3′
Rev 5′ TCATCTTGTATTGTTGGGCTGA 3′ 89
Forward and reverse primers were selected from the 5′ and 3′ region of each gene mRNA. The expected length of each amplicon is indicated
in the right column.
2.7. Protein Extraction and Western Blot
Proteins were extracted using radioimmunoprecipitation assay (RIPA) buffer (Sigma-
Aldrich, Castle Hill, NSW, Australia) containing 1 × Protease Inhibitor cocktail (cOm-
plete™, Mini, EDTA-free Protease Inhibitor Cocktail, Sigma-Aldrich, Castle Hill, NSW,
Australia). Protein was quantified using the Bicinchoninic-Acid (BCA) Assay Protein Assay
Kit (ThermoFisher Scientific) according to manufacturer’s protocol and measured using
the TECAN infinite M1000-PRO ELISA reader at 562 nm.
Samples were prepared by adding 3.75 µL of Laemmli Buffer (Bio-Rad, Gladesville,
NSW, Australia) containing β-mercaptoethanol (Sigma-Aldrich, Castle Hill, NSW, Aus-
tralia) mixture, (ratio 1:9 vol/vol) to 30 µg protein in a final volume of 15 µL. Samples were
then heated for 10 min at 70 ◦C to denature proteins. Proteins were then separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) using 4–20% mini gels (Bio-Rad, Criterion
15-well Mini-Protean SFX), alongside 5 µL of the molecular weight ladder/marker (Bio-Rad
Pre-stained HyperLadder Precision Plus Protein™). Gels were transferred to a PVDF mem-
brane using the Trans-Blot Turbo instrument (Bio-Rad) [33]. Once terminated, membranes
were immediately placed in a container filled with TBS +0.1% Tween 20 (Sigma-Aldrich,
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Castle Hill, NSW, Australia) (TBST 1×) to wash out any residues during transfer. To block
non-specific binding sites, membranes were blocked for 1 h in 5% dry non-fat skim milk in
TBST with slow agitation (50–60 rpm).
Membranes were incubated with appropriately diluted primary antibodies in blocking
buffer overnight at 4 ◦C with slow agitation. The following primary antibodies were used:
GAPDH (VPA00187, Rb, 1:2000, BioRad, Gladesville, NSW, Australia); 5HT1ar (ab85615, Rb,
1:400, Abcam, Cambridge MA, USA). This was followed by incubation with host-specific
secondary antibodies. Membranes were then placed in a container with 1 × TBST and
washed rapidly three times, followed by three further 5 min washes. Finally, membranes
were incubated in secondary antibody (HRP-conjugated goat anti-rabbit IgG) for 1 h at
room temperature, diluted in blocking buffer. The membranes were then washed once
again as previously described to remove excess secondary antibody [34]. Imaging was then
performed on the Bio-Rad ChemiDoc MP Imaging System (Bio-Rad). To detect bands, we
utilized Clarity Western ECL Blotting Substrate (Bio-Rad). Densitometric analyses of bands
was computed using NIH ImageJ (https://imagej.nih.gov/ij/download/ (accessed on 14
January 2021)). Optical densities of target proteins were normalised to those of loading
controls (GAPDH).
2.8. Statistical Analysis
All data are reported as mean ± S.E.M. Statistical analyses were calculated using
GraphPad Prism software ver. 8.4.1 (GraphPad Software, San Diego, California, CA,
USA, www.graphpad.com, accessed on 14 January 2021). Comparisons between two
groups were evaluated using the unpaired two-tailed Student’s t-test. Differences between
three or more groups were analysed using one-way ANOVA and Tukey post-hoc test. To
compute statistical comparisons that involved multiple independent variables, two-way
ANOVA was used followed by Tukey post-hoc test. p values ≤ 0.05 were considered
statistically significant.
3. Results
3.1. Generation of Stable Drd3−/− and Htr1a−/− Cell Lines
We generated stable Drd3−/− and Htr1a−/− cell lines in BV-2 microglial cells to
study the pharmacological effects of buspirone following LPS challenge. BV-2 cells were
transfected with one of two separate Px458 plasmids, one targeting the Drd3 gene and
the other targeting the Htr1a gene (please refer to Supplementary Figure S1 for details).
Sanger sequencing analysis of genomic DNA (for sequencing primers details, please refer
to Table 3) revealed insertions/deletions (indels) in transfected cells (Figure 1A–F). Sanger
sequencing of the alleles of Drd3−/− BV2 cells showed the presence of deletions of either
7 base pairs (BPs) or 10 BPs (Figure 1G), and the alleles of Htr1a−/− cells demonstrated
an insertion of 1 BP or a deletion of 2 BPs (Figure 1G). Amino acid translation from the
sequencing data indicated that all CRISPR-Cas9-induced mutations resulted in early stop
codons (Supplementary Figure S4). Western blot (Figure 1H,I) and real-time qPCR analyses
(Figure 1J) in Drd3−/− cells further confirmed the knockout of the Drd3 protein and
gene (*** p < 0.0001). Similarly, the absence of the 5-HT1Ar protein and gene expression
in Htr1a−/− cells was confirmed by Western blot (Figure 1K,L) and qPCR (Figure 1M,
**** p < 0.0001).




Figure 1. Analyses to confirm stable deletions of the Drd3 or Htr1a genes in BV-2 microglial cells. PCR products of the 
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reveal that there are multiple sequences coming from different alleles, indicating mutation. BP mutations on the majority 
of sequences are shown with red boxes. (A) Chromatogram of the Sanger-sequenced BV-2 wild-type (WT) Drd3+/+ gene. 
(B) Chromatogram of the Sanger-sequenced Drd3 gene on the CRISPR-Cas9 gene edited Drd3−/− clone. (C) Murine Drd3 
gRNA sequence that was inserted into the Px458 plasmid is aligned with the chromatograms as a reference to identify the 
CRISPR-Cas9 cut site. (D) Chromatogram of the Sanger-sequenced BV-2 WT Htr1a gene. (E) Chromatogram of the Sanger-
sequenced Htr1a gene on the Htr1a−/− clone. (F) Murine Htr1a gRNA sequence that was inserted into the Px458 plasmid is 
aligned with the chromatograms as a reference point for the CRISPR-Cas9 cut site. (G) Indel spectrum produced by Track-
ing of Indels by Decomposition: TIDE analysis shows that in the Drd3−/− clone, 38.5% of sequences had a deletion of 10 
base pairs (BPs) and 42.1% of sequences had a deletion of 7 BPs. In the Htr1a−/− clone, there were 38.6% of sequences with 
an insertion of 1 BP and 44.8% of sequences with a deletion of 2 BPs. (H,I) Western blots and (J) real-time qPCR data 
demonstrating negligible Drd3 protein and gene expression Drd3−/− cells. (K,L) Western blots and (M) real-time qPCR data 
demonstrating negligible Htr1a protein and gene expression Htr1a−/− cells. Western blots were performed by resolving 
sample proteins using a gradient 4–20% Tris-glycine SDS-PAGE as previously reported. Bar graphs in I and L depict 
significantly reduced D3r and 5-HT1Ar protein expression in the Drd3−/− and Htr1a−/− clones, respectively. Quantifications 
were performed using the ImageJ software, and normalised values were calculated by dividing the mean optical density 
of bands over the corresponding GAPDH. Data reported as mean ± SEM. Real-time qPCR amplifications were performed 
using selected primer optimised for qPCR analyses (<155 bp length), which recognise fragments within the coding se-
quence of the Drd3 gene (for details refer to Table 2). Fold changes in each gene were obtained after normalisation to the 
endogenous reference gene (S18) and calculated using the comparative ΔΔCt method. *** p < 0.001, **** p < 0.0001 vs. wild-
Figure 1. Analyses to confirm stable deletions of the Drd3 or Htr1a genes in BV-2 microglial cells. PCR products of the Drd3
and Htr1a genes in the WT, Drd3−/− clones and Htr1a−/− clones were seq enced using Sanger met od. Chro atograms of
the sequences w r then analysed using Benchling (https://w .ben ling.com/, accessed on 4 January 2021). Green
peaks = Adenine, red peaks = Thymine, blue peaks = Cytosine, and black peaks = Guanine. Multiple peaks for one BP
reveal that there are multiple sequences coming from different alleles, indicating mutation. BP mutations o the majority
of sequences are shown with red boxes. (A) Chromatogram of the Sanger-sequenced BV-2 wild-type (WT) Drd3+/+ gene.
(B) Chromatogram of the Sanger-sequenced Drd3 gene on the CRISPR-Cas9 gene edited Drd3−/− clone. (C) Murine
Drd3 gRNA sequence h t was inser ed into the Px458 plasmid i aligned with the chromatograms as a reference to
identify the CRISPR-Cas9 cut site. (D) Chromatogram of the Sanger-sequenced BV-2 WT Htr1a gene. (E) Chromatogram
of the Sanger-sequenced Htr1a gene on the Htr1a−/− clone. (F) Murine Htr1a gRNA sequence that was inserted into the
Px458 plasmid is alig ed with the chromatograms as reference point for the CRISPR-Cas9 cut site. (G) Indel spectrum
produced by Tracking of Indels by Decomposition: TIDE analysis shows that in the Drd3−/− clone, 38.5% of sequences
had a deletion of 10 base pa rs (BPs) a d 42.1% of sequences had deletion of 7 BPs. In the Htr1a−/− clone, there were
38.6% of sequences with an insertion of 1 BP and 44.8% of sequences with a deletion of 2 BPs. (H,I) Western blots and
(J) real-time qPCR data demonstrating negligible Drd3 protein and gene expression Drd3−/− cells. (K,L) Western blots
and (M) real-time qPCR data demonstrating negligible Htr1a protein and g ne expressio Htr1a−/− cells. Western blots
were performed by resolving sample proteins using a gradient 4–20% Tris-glycine SDS-PAGE as previously reported.
Bar graphs in I and L depict significantly reduced D3r and 5-HT1Ar protein expression in the Drd3−/− and Htr1a−/−
clones, respectively. Quantifications were performed using the ImageJ software, and normalised values were calculated
by dividing the mean optical density of bands over the corresponding GAPDH. Data reported as mean ± SEM. Real-time
qPCR amplifications were performed using selected primer optimised for qPCR analyses (<155 bp length), which recognise
fragments within the coding sequence of the Drd3 gene (for details refer to Table 2). Fold changes in each gene were
obtained after normalisation to the endogenous reference gene (S18) and calculated using the comparative ∆∆Ct method.
*** p < 0.001, **** p < 0.0001 vs. wild-type as determined by using the unpaired t test. Drd3: murine dopamine D3 receptor
gene, 5-HT1Ar: 5-hydroxytryptamine 1A receptor, Drd3.3: murine dopamine D3 receptor gene knockout clone number
3, Htr1a.2: murine 5-hydroxytryptamine 1A receptor gene knockout clone number 2, RC: reagent control, gRNA: guide
RNA, Ref: reference, S18: ribosomal protein S18, GAPDH: Glyceraldehyde 3-phosphate dehydrogenase, kDa: Kilodalton,
KO: knockout.
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3.2. Establishing the Optimal Buspirone Concentration and Assessing the Effects of Drd3 and
Htr1a Gene Deletions and Buspirone Treatment on Cell Viability Following Exposure to LPS
To investigate the effects of targeted Drd3 and Htr1a gene deletions in BV2 microglial
cell lines before and after LPS challenge, we first established the optimal concentration to
rescue LPS-induced cell polarisation in the absence of overt toxicity. To do so, MTT and
Griess reagent assays were conducted in wild-type BV-2 microglia stimulated with LPS
(1 µg/mL) and increasing concentrations of buspirone (0, 100, 200, 300 and 400 µM) at
24 h. Thereafter, MTT assays were performed under the same experimental conditions in
both wild-type, Drd3−/− and Htr1a−/− cells exposed to LPS or LPS + buspirone (300 µM),
which was found to be the most effective concentration, devoid of toxic activity at the
tested time-point.
As shown in Figure 2A, LPS treatment induced obvious changes in microglial morphol-
ogy (i.e., flattening and swelling of the soma). Co-treatment with increasing concentrations
of buspirone had no significant effect on cell viability up to 400 µM, although cell viability
dropped significantly (24.73% decrease, **** p < 0.0001 vs. LPS and/or untreated controls,
Figure 2B). In terms of NO release (a pro-inflammatory mediator), LPS-induced NO release
was partially rescued with 200µM buspirone (*** p < 0.001 vs. LPS); however complete
recovery was seen at concentrations≥300 µM buspirone (**** p < 0.0001 vs. LPS, Figure 2C).
When comparing the effects of LPS and buspirone across the different genotypes, we ob-
served some genotype-specific changes in cell viability in response to the inflammatory
mimetic and the drug. Specifically, LPS significantly diminished cell viability in Htr1a−/−
cells (** p = 0.007), but not in wild-type or Drd3−/− cultures (non-significant, p > 0.05)
(Figure 2D). At the concentration tested, buspirone was not toxic to wild-type microglial
cells (p = 0.4198) and did not further reduce viability in the Htr1a−/− genotype (p = 0.6758),
whereas it showed significant toxicity in LPS-treated Drd3−/− cells (Figure 2D).
3.3. Nitric Oxide Release in Wild-Type, Drd3−/− and Htr1a−/− Microglial Cells Following LPS
Challenge and Buspirone Treatment
To determine whether genetic deletion of the Drd3 or the Htr1a genes and/or bus-
pirone treatment altered the responsiveness of BV2 microglia to an LPS challenge, we
quantified the levels of nitric oxide (NO) released in supernatants, and measured relative
levels using the Griess reagent assay. In WT cells, LPS significantly increased NO release
(+30%, **** p < 0.0001, Figure 3A). When comparing the effects of LPS stimulation between
wild-type vs. Drd3−/− cells, NO release was significantly reduced (**** p < 0.0001), reaching
levels comparable to those seen in untreated wild-type controls (Figure 3B). Interestingly,
LPS triggered an exaggerated NO release (about 5-fold that of WT cells) in the supernatant
of Htr1a−/− cells (**** p < 0.0001) (Figure 3C).
To determine the specific involvement of the Drd3 or the Htr1a in buspirone’s ability
to mitigate LPS-driven NO release, we measured NO release after co-treatment with
LPS and buspirone across the different genotypes. As shown in Figure 3D, buspirone
reliably diminished the heightened NO levels in LPS-stimulated wild-type microglia
(**** p < 0.0001). However, in Drd3−/− cells, where LPS failed to induce additional NO
release, buspirone was devoid of any biological activity (Figure 3E). Finally, Htr1a−/−
microglial cells also responded reliably to buspirone treatment (**** p < 0.0001), although
NO levels were still around 2.5-fold that of wild-type controls (Figure 3F).




Figure 2. Effects of buspirone on cell viability in wild type, Drd3−/− and Htr1a−/− BV-2 microglial cells after co-treatment LPS 
and buspirone. Cells were either treated with LPS (1 μg/mL), alone or in combination with increasing concentrations of 
buspirone (100, 200, 300 and 400 µM, respectively) for 24 h and representative photomicrographs (using embossing filter 
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Figure 2. Effects of buspirone on cell viability in wild type, Drd3−/− and Htr1a−/− BV-2 microglial cells after co-treatment
LPS and buspirone. Cells were either treated with LPS (1 µg/mL), alone or in combination with increasing concentrations
of buspirone (100, 200, 300 and 400 µM, respectively) for 24 h and representative photomicrographs (using embossing filter
settings) were taken (A). BV-2 cells treated as in A were tested for changes in cell viability (B) or nitric oxide release (C).
Wild-type, Drd3−/− and Htr1a−/− BV-2 cells were treated with LPS and 300µM buspirone for 24 h before cell viability was
assessed (D). Ns = not significant. Data reported is the mean ± SEM from at least two independent experiments. ** p < 0.01,
*** p < 0.001, **** p < 0.0001 as determined by unpaired t-test (A–C) or two-way ANOVA followed by Tukey post-hoc test
(D) Scale bar = 60 µm. WT: wild type, Drd3: murine dopamine D3 receptor gene, Htr1a: murine 5-hydroxytryptamine-1a
receptor gene, LPS: lipopolysaccharide.




Figure 3. Nitrate levels in BV-2 wild type, Drd3−/− and Htr1a−/− cells after treatment with LPS in the presence of buspirone 
or not. Cells were treated for 24 h with either vehicle, 1 μg/mL LPS or 1 μg/mL LPS and 300 μM buspirone. Supernatants 
were then collected and placed in a new 96-well plate and incubated with Griess reagent for 15 min at room temperature, 
then read at 540 nm. Data shown are the optical density (OD), expressed as percentage of untreated WT cells (dotted lines). 
(A) Bar graph showing nitrate levels in wild-type BV-2 cells treated or not with LPS alone for 24 h. (B,C) Comparative 
assessment of NO release between (B) wild-type and Drd3−/− or (C) wild-type and Htr1a−/− cells after treatment with LPS. 
(D–F) Bar graphs depicting NO levels in the supernatants of (D) wild-type, (E) Drd3−/− and (F) Htr1a−/− cells after treatment 
with LPS and buspirone. Values are reported as the percentage NO release of untreated controls (dotted lines, except in 
A). Data reported as mean ± SEM. **** p < 0.0001 vs. LPS or untreated control, as determined by unpaired t-test. 
3.4. Effects of Buspirone Treatment on Inducible Nitric Oxide Synthetase (NOS2) Gene 
Expression in Wild Type, Drd3−/− and Htr1a−/− Knockout Microglial Cells after Exposure to LPS  
In view of the efficacy of buspirone treatment in mitigating the NO induction trig-
gered by LPS in BV-2 cells, we sought to determine if such beneficial effects were also 
associated with transcriptional changes in the mRNA expression of nitric oxide synthase 
2 (NOS2), the gene encoding for inducible nitric oxide synthase (iNOS), an enzyme that 
catalyses the production of NO.  
Comparative analyses of NOS2 transcripts across the different genotypes revealed 
some genotype-dependent changes in gene expression in response to LPS. Specifically, 
LPS-induced NOS2 mRNAs were less pronounced in Drd3−/− microglia compared with 
wild-type (~4.3-fold in Drd3−/− vs. ~65-fold in wild-type cells, Figure 4a) although these 
Figure 3. Nitrate levels in BV-2 wild type, Drd3−/− and Htr1a−/− cells after treatment with LPS in the presence of buspirone
or not. Cells were treated for 24 h with either vehicle, 1 µg/mL LPS or 1 µg/mL LPS and 300 µM buspirone. Supernatants
were then collected and placed in a new 96-well plate and incubated with Griess reagent for 15 min at room temperature,
then read at 540 nm. Data shown are the optical density (OD), expressed as percentage of untreated WT cells (dotted lines).
(A) Bar graph showing nitrate levels in wild-type BV-2 cells treated or not with LPS alone for 24 h. (B,C) Compar tive
asse sment of NO rel ase betwe n (B) wild-type and Drd3−/ or (C) wild-type and Htr1a /− cells after treatment with
LPS. (D–F) Bar graphs depicting NO levels in the super atants of (D) wild-type, (E) Drd3−/− and (F) Htr1a−/− cells after
treatment with LPS and buspirone. Values are reported as the percentage NO release of untreated controls (dotted lines,
except in A). Data reported as mean ± SEM. **** p < 0.0001 vs. LPS or untreated control, as determined by unpaired t-test.
3.4. Effects of Buspirone Treatment on Inducible Nitri Oxide Synthetase (NOS2) Gene Expression
in Wild Type, Drd3−/− and Htr1a−/− Knockout Microglial Cells after Exposure to LPS
In view of the efficacy of buspir ne treatm nt in mitigating th NO induction trigg red
by LPS in BV-2 cells, we sought to determine if such ben ficial effects were also associated
with transcriptional changes in the mRNA expression of nitric oxide synthase 2 (NOS2),
the gene encoding for inducible nitric oxide synthase (iNOS), an enzyme that catalyses the
production of NO.
Comparative analyses of NOS2 transcripts across the different genotypes revealed
some genotype-dependent changes in gene expression in response to LPS. Specifically,
LPS-induced NOS2 mRNAs were less pronounced in Drd3−/− microglia compared with
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wild-type (~4.3-fold in Drd3−/− vs. ~65-fold in wild-type cells, Figure 4A) although these
changes were not statistically significant (p > 0.05, two-way ANOVA followed by Dunnett’s
post-hoc test). In LPS-stimulated Htr1a−/− cells there was a remarkable increase in NOS2
transcripts (**** p < 0.0001 vs. wild-type, Figure 4A).




Figure 4. NOS2 mRNA expression following exposure to LPS and treatment with buspirone for 24 h. Gene expression was 
measured using real-time qPCR and quantified using the ΔΔCt method after normalization to the S18 housekeeping gene. 
(A) Box and whisker plots showing the differential expression of NOS2 transcripts in untreated or LPS-treated wild type, 
Drd3−/− and Htr1a−/− cells or after co-treatment of (B) wild type, (C) Drd3−/− and (D) Htr1a−/− cells with LPS in combination 
with buspirone. All the amplifications were performed using selected primers optimised for qPCR analyses (<155 bp 
length) which recognise fragments within the coding sequence of the gene of interest (for details please refer to Table 4). 
Results are presented as mean fold changes with respect to no treatment (control) ± SEM. Fold changes of each gene were 
obtained after normalisation to the endogenous reference gene. Baseline levels of no treatment groups were set to 1. Sta-
tistically significant data (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001) were determined by one-way or two-way 
ANOVA followed by Tukey and Dunnett’s post-hoc tests. Ns = not significant. 
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was measured using real-time qPCR and quantified using the ∆∆Ct method after normalization to the S18 housekeeping
gene. (A) Box and whisker plots showin e diff rential expression of NOS2 ra scripts in untreated or LPS-treated wild
type, Drd3−/− and Htr1a−/− cells or after co-treatment of (B) wild type, (C) Drd3−/− and (D) Htr1a−/− cells with LPS in
combination with buspirone. All the amplifications were performed using selected primers optimised for qPCR analyses
(<155 bp length) which recognise fragments within the coding sequence of the gene of interest (for details please refer to
Table 4). Results are presented as mean fold changes with respect to no treatment (control) ± SEM. Fold changes of each
gene were obtained a ter normalisatio to the endogen us reference ge e. Baseline levels of no treatment groups were set to
1. Statistically significant data (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001) were determined by one-way or two-way
ANOVA followed by Tukey and Dunnett’s post-hoc tests. Ns = not significant.
When assessing the effects of buspirone within each genotype, buspirone failed to
reduce LPS-driven increases in NOS2 transcripts in wild-type cells (p > 0.05, Figure 4B).
In Drd3−/− microglia, LPS effects on NOS2 mRNA levels were blunted when com-
pared to wild-type cells, but still significantly increased (* p < 0.05 vs. no treatment,
Figure 4C). Treatment with buspirone reduced gene expression, resulting in levels that did
not significantly differ from those of untreated cells (p = 0.3137 vs. no treatment in Drd3−/−
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cells, Figure 4C). By contrast, NOS2 mRNA expression in LPS-exposed Htr1a−/− microglial
showed robust increases (~782-folds vs. no treatment in Htr1a−/− microglia, ** p < 0.01)
which further increased after buspirone treatment, although not at statistically significant
levels (p = 0.07 vs. LPS, Figure 4D).
3.5. Effects of Buspirone Treatment on Interleukin-1β (IL-1β) Gene Expression in Wild Type,
Drd3−/− and Htr1a−/− Knockout Microglial Cells after Exposure to LPS
We used real-time qPCR to determine whether the mRNA expression of the pro-
inflammatory marker interleukin-1β (IL-1β) differed across genotypes in BV-2 cells stimu-
lated with LPS (Figure 5A) or within each genotype after combination treatment with LPS
and buspirone (Figure 5B–D).




Figure 5. IL-1β mRNA expression following exposure to LPS and treatment with buspirone for 24 h. Gene expression was 
measured using real-time qPCR and quantified using the ΔΔCt method after normalization to the S18 housekeeping gene. 
(A) Box and whisker plots showing the differential expression of IL-1β transcripts in untreated or LPS-treated wild type, 
Drd3−/− and Htr1a−/− cells or after co-treatment of (B) wild type, (C) Drd3−/− and (D) Htr1a−/− cells with buspirone. Results are 
presented as mean fold changes with respect to no treatment (control) ± SEM. Baseline levels of no treatment groups were 
set to 1. * p < 0.05 or **** p < 0.0001 vs. no treatment or #### p < 0.0001 vs. LPS were determined by one-way or two-way 
ANOVA followed by Tukey and Dunnett’s post-hoc tests. 
3.6. Effects of Buspirone Treatment on Tumor Necrosis Factor-α (TNF-α) Gene Expression in 
Wild Type, Drd3−/− and Htr1a−/− Knockout Microglial Cells after Exposure to LPS 
Among LPS treated BV-2 cells, we observed a remarkable increase in TNF-α mRNA 
expression (~377-fold increase vs. no treatment), the magnitude of which was not seen in 
Figure 5. IL-1β mRNA expression following exposure to LPS and treatment with buspirone for 24 h. Gene expression
was measured using real-time qPCR and quantifie using the ∆∆Ct method after normalization to the S18 housekeeping
gene. (A) Box and whisker plots showing the differential expression of IL-1β transcripts in untreated or LPS-treated wild
type, Drd3−/− and Htr1a−/− cells or after co-treatment of (B) wild type, (C) Drd3−/− and (D) Htr1a−/− cells with buspirone.
Results are presented as mean fold changes with respect to no treatment (control) ± SEM. Baseline levels of no treatment
groups were set to 1. * p < 0.05 or **** p < 0.0001 vs. no treatment or #### p < 0.0001 vs. LPS were determined by one-way or
two-way ANOVA followed by Tukey and Dunnett’s post-hoc tests.
IL-1β mRNA expression was nota ly higher than controls in wild-type cultures fol-
lowing LPS exposure (~1880-folds of untreated wild-type, **** p < 0.0001 vs. LPS wild-type,
Figure 5A).
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Treatment with buspirone sharply reduced IL-1β mRNA expression (~380-fold of
untreated wild-type, #### p < 0.0001 vs. LPS, Figure 5B), to levels that did not differ
statistically to untreated wild-type controls (p = 0.2434, Figure 5B).
In Drd3−/− cells, drug treatment strongly reduced LPS-driven IL-1β gene expression.
(#### p < 0.0001 vs. LPS, Figure 5C).
Finally, the upregulated IL-1β mRNAs in LPS-stimulated Htr1a−/− microglial cells
were partially reversed by buspirone treatment, although they were still elevated when
compared with no treatment controls (* p < 0.05, Figure 5D).
3.6. Effects of Buspirone Treatment on Tumor Necrosis Factor-α (TNF-α) Gene Expression in Wild
Type, Drd3−/− and Htr1a−/− Knockout Microglial Cells after Exposure to LPS
Among LPS treated BV-2 cells, we observed a remarkable increase in TNF-α mRNA
expression (~377-fold increase vs. no treatment), the magnitude of which was not seen
in either Drd3−/− or Htr1a−/− cells (~42-fold and ~65.82-fold, respectively), in which
TNF-α gene expression was significantly reduced vs. wild-type (**** p < 0.0001 for both,
Figure 6A).
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Figure 6. TNF-α mRNA expression following exposure to LPS and treatment with buspirone for 24 h. Gene expression
was measured using real-time qPCR and quantified using the ∆∆Ct method after normalization to the S18 housekeeping
gene. (A) Box and whisker plots showing he differential expression of TNF-α transcripts in untreated or LPS-treated
wild type, Drd3−/− and Htr1a−/− cells or after co-treatment of (B) wild type, (C) Drd3−/− and (D) Htr1a−/− cells with
LPS in combination with buspirone. Results are presented as mean fold changes with respect to no treatment (control) ±
SEM. Baseline levels of no treatment groups were set to 1. ** p < 0.01 or **** p < 0.0001 vs. no treatment or # p < 0.05 and
#### p < 0.0001 vs. LPS, as determined by one-way or two-way ANOVA followed by Tukey or Dunnett’s post-hoc tests.
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In wild-type BV-2 cells, buspirone potently diminished TNF-α transcripts (~2.87-folds
of no treatment, #### p < 0.0001 vs. LPS, Figure 6B). By contrast, the drug only modestly
reduced TNF-α gene expression in the Drd3−/− and Htr1a−/− cell lineages (# p < 0.05 vs.
LPS for both genotypes, Figure 6C,D).
3.7. Effects of Buspirone Treatment on Arginase 1 (Arg1) Gene Expression in Wild Type, Drd3−/−
and Htr1a−/− Knockout Microglial Cells after Exposure to LPS
Comparative analyses of Arg1 mRNA expression (an anti-inflammatory marker)
across the different genotypes revealed significant differences of gene expression following
LPS exposure (Figure 7A). Specifically, whereas in wild-type BV-2 cells, LPS failed to
induce any significant changes in Arg1 gene expression (p = 0.2963), there was a significant
downregulation in Drd3−/− cells (**** p < 0.0001 vs. LPS-treated wild-type cells, Figure 7A)
and, also to a lesser extent, in Htr1a−/− cells (**** p < 0.0001, Figure 7B).
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(A) Box and whisker plots showing the differential expression of Arg1 transcripts in untreated or LPS-treated wild type, 
Drd3−/− and Htr1a−/− cells or after co-treatment of (B) wild type, (C) Drd3−/− and (D) Htr1a−/− cells with LPS in combination 
with buspirone. Results are presented as mean fold changes with respect to no treatment ± SEM. Baseline levels of no 
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was measured using real-time qPCR and quantified using the ∆∆Ct method after normalization to the S18 housekeeping
gene. (A) Box and whisker plots showing the differential expression of Arg1 transcripts in untreated or LPS-treated wild
type, Drd3−/− and Htr1 −/− cell o after co-treatment f (B) wild type, (C) D d3−/− and (D) Htr1a−/− cells with LPS in
combination with buspirone. Results are presented as mean fold changes with respect to no treatment ± SEM. Baseline
levels of no treatment groups were set to 1. * p < 0.05, ** p < 0.01 or **** p < 0.0001 vs. no treatment or # p < 0.05 vs. LPS, as
determined by one-way or two-way ANOVA followed by Tukey or Dunnett’s post-hoc tests.
In Drd3−/− cells, buspirone did not affect Arg1 mRNA expression (p = 0.5993 vs. LPS-
treated cells, Figure 7C), whereas in Htr1a−/− cells, buspirone treatment rescued the gene
downregulation caused by LPS treatment (# p < 0.05 vs. LPS, Figure 7D).
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3.8. Effects of Buspirone Treatment on Found in Inflammatory Zone 1 (FIZZ1) Gene Expression in
Wild Type, Drd3−/− and Htr1a−/− Knockout Microglial Cells after Exposure to LPS
To provide a balanced panel of both pro- and anti-inflammatory markers in our
assessment of the activities of buspirone, we interrogated an additional microglial anti-
inflammatory marker (i.e., found in inflammatory zone 1 gene, [FIZZ1]) across the different
genotypes following exposure to LPS, and then within each genotype, to assess the effect
of combined treatment with LPS and buspirone.
When comparing LPS-stimulated wild-type vs. Drd3−/− cultures, there were no
significant differences in FIZZ1 gene expression (p = 0.7956 vs. LPS-treated wild-type cells,
Figure 8A). However, we found a statistically significant increase in gene expression in
Htr1a−/− cells (** p < 0.01, Figure 8A). Interestingly, buspirone significantly increased FIZZ1
mRNA expression in LPS-stimulated, wild-type microglia (## p < 0.01 vs. LPS-treated
wild-type cells, Figure 8B), but had no significant effect on LPS-treated Drd3−/− cultures
(p = 0.9734, Figure 8C), whilst it triggered a moderate and significant gene upregulation in
Htr1a−/− cells (* p < 0.05 vs. no treatment group, Figure 8D).




Figure 8. FIZZ1 mRNA expression following exposure to LPS and treatment with buspirone for 24 h. Gene expression 
was measured using real-time qPCR and quantified using the ΔΔCt method after normalization to the S18 housekeeping 
gene. (A) Box and whisker plots showing the differential expression of FIZZ1 transcripts in untreated or LPS-treated wild 
type, Drd3−/− and Htr1a−/− cells or after co-treatment of (B) wild type, (C) Drd3−/− and (D) Htr1a−/− cells with LPS in combi-
nation with buspirone. Results are presented as mean fold changes with respect to no treatment ± SEM. Fold changes in 
each gene were obtained after normalisation to the endogenous reference gene. Baseline levels of no treatment groups 
were set to 1. * p < 0.05, ** p < 0.01 or *** p < 0.001 vs. no treatment or ## p < 0.01 vs. LPS, as determined by one-way or two-
way ANOVA followed by Tukey or Dunnett’s post-hoc tests. Ns = not significant. 
Figure 8. FIZZ1 mRNA expression following exposure to LPS and treatment with buspirone for 24 h. Gene expression
was measured using real-time qPCR and quantified using the ∆∆Ct method after normalization to the S18 housekeeping
gene. (A) Box and whisker plots showing the differential expression of FIZZ1 transcripts in untreated or LPS-treated wild
type, Drd3−/− and Htr1a−/− cells or after co-treatment of (B) wild type, (C) Drd3−/− and (D) Htr1a−/− cells with LPS in
combination with buspirone. Results are presented as mean fold changes with respect to o treatment ± SEM. Fold changes
in each gene were obtained after normalisation to the endogenous reference gene. Baseline levels of no treatment groups
were set to 1. * p < 0.05, ** p < 0.01 or *** p < 0.001 vs. no treatment or ## p < 0.01 vs. LPS, as determined by one-way or
two-way ANOVA followed by Tukey or Dunnett’s post-hoc tests. Ns = not significant.
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4. Discussion
This is the first study, to the best of our knowledge, which describes the anti-inflammatory
effects of buspirone in BV-2 microglial cells after LPS challenge and investigates the in-
volvement of the genes for Drd3 and Htr1a in mediating beneficial drug-induced effects.
Buspirone has been available on the market for decades in view of its beneficial activities
for the treatment of generalised anxiety disorder. Its central activity is still achieved despite
low systemic bioavailability. In fact, when administered, buspirone is extensively metab-
olized due to its extensive first pass metabolism, where it undergoes hepatic oxidation
mediated by the CYP3A4 enzyme. Hydroxylated derivatives are produced, including a
pharmacologically active metabolite 1-pyrimidinylpiperazine (1-PP), which seems to par-
ticipate in the biological activity of the drug [35]. Buspirone has a relatively low solubility
and there is no documented evidence of active transport mechanisms through the blood
brain barrier; nonetheless, as highlighted by an [11C]-(+)-PHNO occupancy study the drug
reaches Drd3-rich CNS targets, where it exerts clear Drd3 antagonist activity [36]. These
results pinpoint how buspirone may display some degree of permeability in the BBB.
Using CRISPR-Cas9 technology, we selectively knocked out buspirone’s best-known
pharmacological targets to create a robust in vitro platform to gain novel molecular in-
sights into the mechanism of action of buspirone and other drugs targeting these receptor
types. Our findings demonstrate that buspirone treatment and the genetic deletion of
Drd3 attenuates LPS-triggered inflammation in microglia cell lines. In addition, we have
identified a novel biological role of the Htr1a gene in controlling microglial cell viability
and NOS2-mediated nitric oxide production after LPS insult.
4.1. Targeting Drd3 and Htr1a Genes to Study the Effects of Buspirone in Microglial Cells
A major reason for the generation of stable knockout BV-2 microglial cell lines using
CRISPR-Cas9 gene editing technology was to develop a cellular platform that could help
in unveiling the pharmacological activity of buspirone in microglial cells exposed to an
inflammatory challenge with LPS. This approach was essential to overcome any issues
associated with transient reduction of gene expression using either short-interfering RNA
methods, or other gene knockdown strategies, which only attenuate gene expression for a
limited time, and do not always recapitulate the biological effects achieved with total gene
ablation with high fidelity. We have provided supplementary data detailing the general
workflow (i.e., plasmid packaging, transfection, single-cell sorting of transfected cells and
confirmation of gene deletions (Supplementary Figures S1–S4). Analyses of the mutations
induced by CRISPR-Cas9 in clonal populations revealed the presence of insertion/deletions
(indels) on up to four alleles instead of two. Interestingly, this phenomenon was reported
in the same cell line after CRISPR-Cas9 editing of the gene TREM2 [37]. Although the
reasons why this occurs is not known, one possibility is the aneuploidy of the target
chromosome(s) (i.e., tetrasomy). This would explain why CRISPR-Cas9 gene editing was
particularly challenging in BV-2 cells in comparison to what would be expected from
cells harboring the traditional bi-allelic configuration, as the chances of the CRISPR-Cas9
plasmid binding to all alleles are significantly reduced with twice the number of alleles.
However, despite these challenges, we succeeded in generating complete gene knockout
cell lines for each of the selected gene targets, providing a reliable and potentially scalable
in vitro platform at a relatively low cost. Additionally, these protocols are now optimized
and can be readily adapted to create a potent pharmacological tool to gain mechanistic
insights on the pharmacology of both old and new drug targets [38].
Our CRISPR-Cas9 gene knockouts were confirmed both by Western blot and real-time
qPCR. Frameshift mutations within the Drd3 and Htr1a coding sequences were translated
as truncated and non-functional proteins, whose expression was either strongly reduced
or not detected (Figure 1H,I,K,L). Accordingly, Drd3 and Htr1a mRNA studies confirmed
negligible transcript levels in the two knockout cell lines (Figure 1J). It should be noted that
some residual D3r protein expression was detected in the Drd3−/− microglia (Figure 1H,I).
This can be explained by the fact that there are no commercially available antibodies that
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are specific to the D3r, as its amino acid sequence is highly homologous with that of other
D2-like receptor subtypes, including the D2r and D4r [39], which also exhibit overlapping
molecular weights. Therefore, the residual faint bands shown in Drd3−/− cells could be
non-specific binding to any of these two receptors.
4.2. Genotype-Specific and Drug-Related Changes in BV-2 Cell Viability and Nitric Oxide Release
after LPS Challenge
Upon exposure to LPS, wild-type BV-2 microglia displayed signs of activation. How-
ever, buspirone dose-dependently reversed this process without significant toxic effects at
concentrations up to 300 µM, which was also accompanied by a remarkable attenuation
of nitrates in culture media (Figure 2). When comparing the effects of LPS and buspirone
across the different genotypes, we found that exposure to LPS (1 µg/mL) slightly increased
cell viability irrespective of genotype, surpassing levels of matched untreated controls,
suggesting that the inflammatory mimetic might exert some growth-promoting effects.
Similar results have previously been reported by another in vitro study that demonstrated
an increase in the survival rate of BV-2 cells following exposure to the same concentration
of LPS used in this study after exposures of 24 and 40 h [40]. In addition, our data are
further supported by several in vivo studies that reported an increase in microglial cell
proliferation in adult mice following a single dose of LPS [41,42].
With regards to BV-2 cell viability and nitric oxide release, our results using the
Htr1a−/− cell line were totally unexpected. To the best of our knowledge, there are no
reports on the effects mediated by the 5-HT1Ar on microglia. We found that baseline cell
viability in Htr1a−/− microglia was significantly reduced compared with WT controls, both
in LPS and cells treated with both LPS and buspirone. As there were no changes in viability
resulting from the deletion of the Drd3 gene, these findings suggest that the Htr1a might
play a critical role in regulating the metabolic activity of these cells. A few studies have
shown that microglia express functional serotonin receptors which are linked to distinct
microglial properties and cellular interactions [43,44]. Our study provides unprecedented
data supporting a functional role of the 5-HT1Ar in regulating BV-2 microglia cell viability.
The degeneration of dopaminergic neurons has been linked to the robust upregu-
lation of inducible nitric oxide synthase (NOS2) and production of neurotoxic levels of
NO [45]. Our data show that Htr1a gene ablation in BV-2 cells exposed to LPS results in an
exaggerated production of NO. These data were confirmed by analyses of NOS2 mRNA
expression, a gene that regulates the production of NO through the expression of NOS2.
This result complements an earlier study by Zhang and collaborators [46], which found
that the 5-HT1Ar agonist 8-OH-DPAT downregulated the neuronal-specific nitric oxide
synthase (nNOS) expression and the 5-HT1Ar selective antagonist NAN-190 upregulated
nNOS expression [46]. Based on these results, we are tempted to believe that stimulation of
the 5-HT1Ar may hinder the activity of the NOS2/NO pathway, whilst gene ablation may
do the opposite. Importantly, buspirone itself was able to decrease NO production in both
WT and Htr1a−/− cells co-treated with LPS.
This novel finding suggests that the decrease in NO levels seen after buspirone treat-
ment is most likely due to the antagonist activity of the Drd3 and not the agonist function on
5-HT1Ar. This is further supported by the data obtained in Drd3−/− cultures, where stimu-
lation with LPS failed to increase NO and only marginally increased NOS2 gene expression,
in alignment with the idea that Drd3 antagonism attenuates neuroinflammation [47,48].
4.3. Genotype-Specific and Drug-Related Changes of Pro-Inflammatory Cytokines in LPS-Stimulated
BV-2 Microglia
Both IL-1β and TNF-α have been implicated as main effectors of the neuroinflam-
matory machinery activated during neurodegeneration in models of PD [48]. Moreover,
the exogenous administration of both cytokines has been shown to exacerbate 6-OHDA-
induced cell death [48]. In this study, we first established whether LPS stimulation triggered
the induction of IL-1β and TNF-α gene expression and then identified if there were specific
differences in the expression profile of these pro-inflammatory across genotypes and in
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response to buspirone treatment. As expected, LPS challenge robustly increased the ex-
pression of both cytokines (in the order of about 2000-fold). In Drd3−/− and, to a lesser
extent, in Htr1a−/− cells, LPS-driven IL-1β and TNF-α gene induction were much more
blunted than in WT cells, providing additional evidence for a role of the Drd3 (and perhaps
the Htr1a) in mitigating LPS-induced inflammation. The latter consideration is in view
of the effects seen after drug treatment in both genotypes, where buspirone further pre-
vented the upregulation of both pro-inflammatory cytokines in both genotypes (Drd3−/−
and Htr1a−/− BV-2 cells, respectively). This corroborates the findings in murine models,
showing that either IL-1β or TNF-α induction are attenuated by xaliproden or 8-OH-DPAT,
two 5-HT1Ar agonists [49,50]. However, the study highlights the predominant role of the
Drd3 blockage as the main route to provide an anti-inflammatory activity in BV-2 microglia,
which is supported further by evidence showing that Drd3 agonists trigger TNF-α gene
upregulation [51].
4.4. Genotype-Specific and Drug-Related Changes of Anti-Inflammatory Cytokines in
LPS-Stimulated BV-2 Microglia
In addition to pro-inflammatory cytokines, we also analysed the expression levels of
the anti-inflammatory cytokines Arg1 and FIZZ1. Our study showed that, in untreated cells,
neither of these cytokines were affected across the genotypes (WT, Drd3−/−, Htr1a−/−).
When cells were challenged with LPS, consistent with previous evidence using similar
experimental paradigms [52–54], FIZZ1 gene expression was unaffected, whereas Arg1
mRNAs were diminished in both Drd3−/− and Htr1a−/− cells. Treatment with buspirone
was unable to rescue Arg1 gene downregulation in WT and Drd3−/− cells but was effective
in restoring gene expression in Htr1a−/− cells, suggesting a more complex interaction
between the Drd3 and 5HT1ar in regulating Arg1 transcription. In contrast, FIZZ1 mRNA
expression was strongly increased in response to buspirone treatment in WT BV-2 cultures,
but not in Drd3−/− cells and only marginally in Htr1a−/− cells. Taken together, this evidence
supports the notion that, during an LPS challenge, the Drd3 antagonist activity of bus-
pirone is required to convey its anti-inflammatory response. Similar to recent reports from
Pacheco and co-workers in a PD model [14] and in a model of methamphetamine-induced
intoxication [55], our findings reveal a critical role for Drd3 in modulating the inflamma-
tory response. The upregulation of anti-inflammatory cytokines in microglia is considered
critical in slowing the progression of PD and other neurodegenerative conditions, as
this promotes the acquisition of the M2 anti-inflammatory phenotype by microglia [56].
PG01037, a potent Drd3 antagonist, reduced microglia activity, thereby contributing to an
overall anti-inflammatory and therapeutic effect in PD mouse models [25].
Despite the promising results of this study, it is important to note that microglia are
not the only cells contributing to the chronic inflammatory milieu in the CNS of people
afflicted by neurological disorders. Astrocytes constitute the majority of the brain’s glial
cell population and communicate closely with microglia to respond to neuronal damage,
inflammatory and pathological stimuli. Montoya and colleagues [14] demonstrated that
the Drd3s are expressed on astrocytes and that Drd3 deficiency in astrocytes attenuates
microglial activation upon systemic inflammation and exacerbated the expression of the
anti-inflammatory FIZZ1 gene [14]. Furthermore, the lack of Drd3 expression in astro-
cytes promotes beneficial astrogliosis, which exerts anti-inflammatory and neuroprotective
functions [25]. These beneficial actions of Drd3 blockade on astrocytes are particularly
important in neurological diseases associated with neuroinflammation as it has been shown
that, during chronic neuroinflammation, astrocytes alter the permeability of the blood
brain barrier to promote the infiltration of peripheral immune cells to further promote neu-
roinflammation. These studies suggest that buspirone’s anti-inflammatory activities may
not be restricted to microglia, and that its Drd3 antagonist activity on astrocyte might elicit
synergistic effects via alternative mechanisms that culminate in a robust anti-inflammatory
effect that also promotes neuroprotection.
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5. Conclusions
In conclusion, in the present manuscript, we show that either Drd3 gene deletion or
buspirone treatment reliably attenuated LPS-triggered inflammation in BV-2 microglia.
Additionally, we are the first to demonstrate the functional role of the 5-HT1Ar in regulating
cell viability and NO release in polarised microglia. The ability of both the Drd3 gene
deletion and buspirone treatment and, to a lesser extent, Htr1a gene ablation, to reduce
inflammation in microglia suggests that buspirone holds the potential to be repurposed as
an effective anti-inflammatory agent to treat those neurological diseases associated with
chronic neuroinflammation, including Parkinson’s disease. In addition, considering that
there is some evidence suggesting that buspirone may also exert stimulatory activities
in immune cells of the periphery, such as CD4+ T lymphocytes [57] and natural killer
cells [58], in vivo work is warranted to better elucidate the full potential of this drug in
the CNS.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cells10061312/s1, Figure S1: Design of the Px458 plasmid for the murine Drd3 and Htr1a
gene KOs and inserted their gRNA sequences. (A) General design of the Px458 plasmid, depicting
the key features: human U6 promoter, gRNA sequences which were designed to bind specifically
to the DNA of target genes, Cas9 protein, GFP, and ampicillin resistance. (B,C) Chromatograms
created in Benchling from Sanger sequencing results and aligned gRNA sequences. Green peaks
indicate an Adenine base, red peaks indicate a Thymine base, blue peaks indicate a Cytosine base
and black peaks indicate a Guanine base. (B) Sequencing of the Drd3 plasmid indicates an incorrect
BP of Guanine instead of Cytosine represented by the red box, however, there is still a blue peak for
Cytosine, so this is likely sequencing error. (C) Sequencing results of the Htr1a plasmid shows correct
alignment of the gRNA sequence. GFP: green fluorescent protein, gRNA: guide RNA, BP: base pairs,
CRISPR: clustered, regularly interspaced short palindromic repeats. Drd3: murine dopamine D3
receptor gene, Htr1a: murine 5-hydroxytryptamine-1a receptor gene. Figure S2: Images of transfected
BV-2 cells and fluorescence scatter dot plots displaying the gating of the GFP positive cells. Cells
were seeded 1 × 105 cells per well in 12-well plates and transfected with the appropriate plasmids.
(A–C) Images of cells captured on a light microscope the day after transfection. (D–F) Images of
cells under a light microscope with a GFP filter taken the day after transfection to illustrate the
expression of GFP (shown by white arrow heads). (G–I) Each dot represents a single cell passing
through the Fluorescence Activated Cell Sorting MoFlo© Astrios flow cytometer for sorting. The
parameter for the horizontal axis of the dot plot is a Bandpass filter of 530/40 with a laser of 488 nm.
The parameter for the vertical axis is a 750 longpass (LP) filter. (G) Dot plot of the BV-2 WT cells
illustrates the GFP negative cells and therefore acts as a guide for gating the GFP positive cells as
demonstrated with the orange box. (H,I) Dot plots of the BV-2 cells transfected with the CRISPR-
Cas9 plasmids display the GFP positive cells gated inside the orange box. GFP: green fluorescent
protein, WT: Wild type, KO: knockout, Drd3: murine dopamine D3 receptor gene, Htr1a: murine
5-hydroxytryptamine-1a receptor gene. Figure S3: DNA agarose gel electrophoresis (AGE) confirms
that end-point PCR amplified Drd3 and Htr1a genes correctly. Cells were seeded 3 × 105 cells per
well in a 6-well plate, and DNA was extracted using ISOLATE II Genomic DNA Kit (Bioline). End
point PCR was conducted using primers to target the genes of interest (for details refer to Table 2),
and AGE confirmed the PCR was successful. Lane 1 is the DNA ladder (Hyperladder 1KB). Lane
2 is end-point PCR product of the Drd3 gene from BV-2 cells. Lane 3 is end-point PCR product of
the Htr1a gene from BV-2 cells. BP: base pair, Drd3: murine dopamine D3 receptor gene, Htr1a:
murine 5-hydroxytryptamine-1a receptor gene. Figure S4: DNA sequence and amino acid translation
showing early stop codons in the Drd3−/− and Htr1a−/−. End-point PCR products were Sanger
sequenced and analysed through the program Tracking of Indels by Decomposition: TIDE. Amino
acid translation was undertaken using Benchling. The corresponding amino acids for each codon
are illustrated by coloured segments underneath the BPs in the DNA sequence. The number above
each amino acid is indicative of the amino acid’s position in the aligned sequence in Benchling. The
amino acids representing the stop codons are represented by the star symbol and are sur-rounded by
red circles. Indels are illustrated by red boxes around the affected BPs. (A) Amino acid translation
from Sanger se-quencing results of the Drd3−/− indicates a deletion of 7 base pairs (BPs) and a
deletion of 10 BPs. These resulted in frame-shift mu-tations and thus a change in the codons and the
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corresponding amino acid sequence compared to the WT. (B) Amino acid transla-tion from Sanger
sequencing results of Htr1a−/− reveal an insertion of 1 BP and deletion of 2 BPs, also resulting in
frameshift muta-tions. WT: Wild type, A: adenine, T: thymine, C: cytosine, G: guanine. Drd3: murine
dopamine D3 receptor gene, Htr1a: murine 5-hydroxytryptamine-1a receptor gene.
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